Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis

Cancer Immunology Immunotherapy

Volumn 49, Issue 6, 2000, Pages 335-345

  Verneris, M R ^a   Kornacker, M ^a   Mailander, V ^a   Negrin, R S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; CD95; Gene expression; Immunotherapy; Lymphocyte activation

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; CYTOKINE; FAS ANTIGEN; PROTEIN BCL 2; PROTEIN BCL X; SURVIVIN;

APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; KILLER CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; T LYMPHOCYTE ACTIVATION;

EID: 0033856842     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620000111     Document Type: Article

References (74)

1. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation
2. Fas ligand mediates activation-induced cell death in human T lymphocytes
3. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
4. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma
5. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas
6. Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide
7. Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis
8. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule
9. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis
10. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis
11. Interaction of CED-4 with CED-3 and CED-9: A molecular framework for cell death
12. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)
13. Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance
14. Ex vivo malignant glioma cells are sensitive to Fas (CD95/APO-1) ligand-mediated apoptosis
15. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells
16. Interactions among subunits of the oligosaccharyltransferase complex
17. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells
18. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells
19. Fas ligand expresston in glioblastoma cell lines and primary astrocytic brain tumors
20. Death of solid tumor cells induced by Fas ligand expressing primary myoblasts
21. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: In vitro and in vivo efficacy in severe combined immunodeficiency disease mice
22. Inhibition of death receptor signals by cellular FLIP
23. Effects of differential overexpresston of Bcl-2 on apoptosis, proliferation, and telomerase activity in Jurkat T cells
24. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation
25. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity
26. Metalloproteinase-mediated release of human Fas ligand
27. DAD1, the defender against apoptotic cell death, is a subunit of the mammalian oligosaccharyltransferase
28. Activation interferes with the APO-1 pathway in mature human T cells
29. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation
30. Regulation of CD95 (Fas) ligand expression by TCR-mediated signaling events
31. Control of apoptosis and mitotic spindle checkpoint by survivin
32. Interferon gamma plays a critical role in induced cell death of effector T cell: A possible third mechanism of self-tolerance
33. A novel population of expanded human CD3+ CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency
34. Fas and FasL in the homeostatic regulation of immune responses
35. Release of preformed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat T cells
36. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells
37. The permeability transition pore complex: A target for apoptosis regulation by caspases and bcl-2-related proteins
38. + killer cells
39. Fas ligand expression in nodal non-Hodgkin's lymphoma
40. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex
41. Human lung carcinomas express Fas ligand
42. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
43. The Fas counterattack: A molecular mechanism of tumor immune privilege
44. Comparative studies of CD3- and CD3+CD56+ cells: Examination of morphology, function, T cell receptor rearrangement and pore-forming protein expression
45. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement
46. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes
47. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis
48. Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis
49. + CTL clones resist Fas ligand- induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing
50. Interferon-alpha enhances CD95L-induced apoptosis of human malignant glioma cells
51. FAP-1: A protein tyrosine phosphatase that associates with Fas
52. A subset of natural killer cells in peripheral blood displays a mature T cell phenotype
53. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity
54. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells
55. Propagation of large numbers of T cells with natural killer cell markers
56. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells
57. Confirmation of the Fas counterattack in host-tumor relations
58. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas
59. Purification and characterization of the Fas-ligand that induces apoptosis
60. Human Fas ligand: Gene structure, chromosomal location and species specificity
61. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs (in Process Citation)
62. Downregulation of Fas ligand by shedding
63. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis
64. Role of Fas ligand (CD95L) in immune escape: The tumor cell strikes back
65. A highly conserved apoptotic suppressor gene is located near the chicken T-cell receptor alpha chain constant region
66. Th1 and Th2 subsets equally undergo Fas-dependent and -independent activation-induced cell death
67. Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas-mediated apoptosis
68. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-down-regulated with the receptor of tumor necrosis factor
69. The DAD1 protein, whose defect causes apoptotic cell death, maps to human chromosome 14
70. Mitochondrial control of nuclear apoptosis
71. Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: A lethal two-way street
72. A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells
73. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mortl
74. Characterization of apoptosis-resistant antigen-specific T cells in vivo